- Home
- GLSI vs IKT Comparison
GLSI vs IKT Comparison
Compare GLSI & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- IKT
- Stock Information
- Founded
- GLSI 2006
- IKT 2008
- Country
- GLSI United States
- IKT United States
- Employees
- GLSI N/A
- IKT N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- GLSI Health Care
- IKT Health Care
- Exchange
- GLSI Nasdaq
- IKT Nasdaq
- Market Cap
- GLSI 134.6M
- IKT 140.5M
- IPO Year
- GLSI 2020
- IKT 2020
- Fundamental
- Price
- GLSI $10.08
- IKT $1.80
- Analyst Decision
- GLSI Strong Buy
- IKT Buy
- Analyst Count
- GLSI 1
- IKT 2
- Target Price
- GLSI $39.00
- IKT $8.00
- AVG Volume (30 Days)
- GLSI 54.6K
- IKT 528.7K
- Earning Date
- GLSI 08-13-2025
- IKT 08-13-2025
- Dividend Yield
- GLSI N/A
- IKT N/A
- EPS Growth
- GLSI N/A
- IKT N/A
- EPS
- GLSI N/A
- IKT N/A
- Revenue
- GLSI N/A
- IKT N/A
- Revenue This Year
- GLSI N/A
- IKT N/A
- Revenue Next Year
- GLSI N/A
- IKT N/A
- P/E Ratio
- GLSI N/A
- IKT N/A
- Revenue Growth
- GLSI N/A
- IKT N/A
- 52 Week Low
- GLSI $8.06
- IKT $1.12
- 52 Week High
- GLSI $17.00
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- GLSI 53.55
- IKT 45.45
- Support Level
- GLSI $8.97
- IKT $1.81
- Resistance Level
- GLSI $11.52
- IKT $2.09
- Average True Range (ATR)
- GLSI 0.53
- IKT 0.14
- MACD
- GLSI 0.14
- IKT 0.01
- Stochastic Oscillator
- GLSI 49.53
- IKT 45.28
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.